The UK's deliberations on cost-effectiveness of vaccines have came under scrutiny, as members of parliament probed the controversy around GlaxoSmithKline's Bexsero meningitis B jab. MPs quizzed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback